Tau Pathology Triggered by Spinal Cord Injury Can Play a Critical Role in the Neurotrauma Development

• Published in: Molecular neurobiology 2020-11, Vol.57 (11), p.4845-4855
• Main Authors: Nakhjiri, Elnaz, Vafaee, Manuchehr S., Hojjati, Seyed Mohammad Massod, Shahabi, Parviz, Shahpasand, Koorosh
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cell Biology; Central nervous system; Cerebrospinal fluid; Neurobiology; Neurodegeneration; Neurodegenerative diseases; Neurological complications; Neurology; Neurosciences; Neurotoxicity; Pathogenicity; Pathology; Phosphorylation; Spinal cord injuries; Tau protein; Trauma; Traumatic brain injury
• ISSN: 0893-7648; 1559-1182
• DOI: 10.1007/s12035-020-02061-7

Traumatic spinal cord injury (SCI) can result in substantial neurological impairment along with significant emotional and psychological distress. It is clear that there is profound neurodegeneration upon SCI, gradually spread to other spinal cord regions and brain areas. Despite extensive considerations, it remains uncertain how pathogenicity diffuses in the cord. It has been reported that tau protein abnormal hyperphosphorylation plays a central role in neurodegeneration triggered by traumatic brain injury (TBI). Tau is a microtubule-associated protein, heavily implicated in neurodegenerative diseases. Importantly, tau pathology spreads in a traumatic brain in a timely manner. In particular, we have recently demonstrated that phosphorylated tau at Thr231 exists in two distinct cis and trans conformations, in which that cis P-tau is extremely neurotoxic, has a prion nature, and spreads to various brain areas and cerebrospinal fluid (CSF) upon trauma. On the other hand, tau pathology, in particular hyperphosphorylation at Thr231, has been observed upon SCI. Taken these together, we conclude that cis pT231-tau may accumulate and spread in the spinal cord as well as CSF and diffuse tau pathology in the central nervous system (CNS). Moreover, antibody against cis P-tau can target intracellular cis P-tau and protect pathology spreading. Thus, considering cis P-tau as a driver of tau pathology and neurodegeneration upon SCI would open new windows toward understanding the disease development and early biomarkers. Furthermore, it would help us develop effective therapies for SCI patients.